Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.
Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.
复制标题
DOI：
10.2217/rme.10.38
复制
发表时间：
2010-07
影响因子：
2.7
通讯作者：
Cheng L
中科院分区：
文献类型：
--
作者：
Ye Z;Cheng L
人类诱导多能干细胞（iPS）已经从包括血细胞在内的各种细胞类型产生，并且作为重新编程出生后体细胞的起始群体提供某些优势。与成体干细胞不同，iPS细胞可以在培养中无限增殖，同时保留其分化为任何细胞类型的潜力，包括造血谱系。患者特异性iPS细胞的衍生与改进的造血分化方案相结合，提供了产生用于骨髓移植的组织相容性干细胞的替代方案。此外，重新编程血细胞和将iPS细胞重新分化回造血谱系的能力为建立获得性和遗传性血液疾病的新模型提供了机会。本文就血细胞来源的iPS细胞及其向造血细胞分化的研究进展作一综述。将讨论血液作为重编程来源的优势以及在再生医学中的应用。
Human induced pluripotent stem (iPS) cells have been generated from various cell types including blood cells, and offer certain advantages as a starting population for reprogramming postnatal somatic cells. Unlike adult stem cells, iPS cells can proliferate limitlessly in culture while retaining their potential to differentiate into any cell type, including hematopoietic lineages. Derivation of patient-specific iPS cells, in combination with improved hematopoietic differentiation protocols, provides an alternative to generate histocompatible stem cells for bone marrow transplantation. In addition, the ability to reprogram blood cells and redifferentiate iPS cells back to hematopoietic lineages provides opportunities to establish novel models for acquired and inherited blood diseases. This article will summarize recent progress in human iPS cells derived from blood cells and hematopoietic differentiation from iPS cells. Advantages of blood as a source for reprogramming and applications in regenerative medicine will be discussed.